Amicus Therapeutics Inc
Company Profile
Business description
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Contact
47 Hulfish Street
PrincetonNJ08542
USAT: +1 609 662-2000
E: ir@amicusrx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
499
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,467.00 | 4.40 | 0.05% |
| CAC 40 | 7,858.47 | 114.72 | 1.48% |
| DAX 40 | 23,899.31 | 399.99 | 1.70% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,621.78 | 66.98 | 0.78% |
| HKSE | 23,603.86 | 736.12 | 3.22% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 4.03 | -0.07% |
| S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
| SSE Composite Index | 3,369.24 | 27.25 | 0.82% |